Everything below concerns research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Breastfeeding delays the return of menstruation, and in very specific circumstances, fertility, a phenomenon known as lactational amenorrhea. Long-term benefits for the mother include decreased risk of breast cancer, cardiovascular disease, diabetes, metabolic syndrome, and rheumatoid arthritis. Breastfeeding is less expensive than infant formula, but its impact on mothers' ability to earn an income is not usually factored into calculations comparing the two feeding methods. It is also common for women to experience symptoms such as: vaginal dryness, De Quervain syndrome, cramping, mastitis, moderate to severe nipple pain, and a general lack of bodily autonomy. These symptoms generally peak at the start of breastfeeding but disappear or become considerably more manageable after the first few weeks. Each feeding may last as long as 30–60 minutes, as milk supply develops and the infant learns the Suck-Swallow-Breathe pattern. However, as milk supply increases and the infant becomes more efficient at feeding, the duration of feeds may shorten to as little as 5-10 minutes per breast. While newborns and young babies feed 8-12 times per 24 hours, older infants may feed less often. When direct breastfeeding is not possible, expressing or pumping to empty the breasts can help mothers avoid plugged milk ducts and breast infection, maintain their milk supply, resolve engorgement, and provide milk to be fed to their infant at a later time. Medical conditions that do not allow breastfeeding are rare.
=== Competition binding === Competition binding is used to determine the presence of selectivity for a particular ligand for receptor sub-types, which allows the determination of the density and proportion of each sub-type in the tissue. Competition curves are obtained by plotting specific binding, which is the percentage of the total binding, against the log concentration of the competing ligand. A steep competition curve is usually indicative of binding to a single population of receptors, whereas a shallow curve, or a curve with clear inflection points, is indicative of multiple populations of binding sites.
==== Early domestic and foreign policy ==== In an effort to reduce overcrowding, on 15 December Noboa proposed deporting 1,500 foreign prisoners who are incarcerated in Ecuador. He also said he would consider constructing two maximum security prisons, drawing inspiration from El Salvador. The same day, Noboa announced he would seek to cut $1 billion in government spending while raising revenue via gold reserves worth around $300 million. Noboa addressed the UN Security Council On 9 December, highlighting criminal gang activities and overall security as high priorities. On 10 December 2023, Noboa attended the inauguration of Argentinian President Javier Milei. Noboa also met with Ukrainian President Volodymyr Zelenskyy, who praised him for his stance on Russia's invasion. The two discussed expanding bilateral relations, primarily surrounding security and trade. Zelenskyy also invited Noboa to visit Ukraine.
Depending on manufacturer, the dressings are available in transparent, translucent, or opaque varieties. Certain brands will develop a wider opaque area when saturated with exudate, which is sometimes a suggested indicator of when to replace them. The moist conditions produced under the dressing are intended to promote wound healing, including fibrinolysis and angiogenesis, without causing softening and breakdown of tissue. Most hydrocolloid dressings are water-resistant, allowing gentle washing and bathing.
Sources: en.wikipedia.org
=== Books and book chapters === Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald's Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-editors of Braunwald's Heart Disease. Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor.
Sucrose gradient centrifugation—a linear concentration gradient of sugar (typically sucrose, glycerol, or a silica-based density gradient media, like Percoll)—is generated in a tube such that the highest concentration is on the bottom and lowest on top. A protein sample is then layered on top of the gradient and spun at high speeds in an ultracentrifuge. This causes heavy macromolecules to migrate towards the bottom of the tube faster than lighter material. During centrifugation in the absence of sucrose, as particles move farther and farther from the center of rotation, they experience more and more centrifugal force (the further they move, the faster they move). The problem with this is that the useful separation range within the vessel is restricted to a small observable window. Spinning a sample twice as long does not mean the particle of interest will go twice as far; in fact, it will go significantly further. However, when the proteins are moving through a sucrose gradient, they encounter liquid of increasing density and viscosity. A properly designed sucrose gradient will counteract the increasing centrifugal force so the particles move in close proportion to the time they have been in the centrifugal field. Samples separated by these gradients are referred to as "rate zonal" centrifugations. After separating the protein/particles, the gradient is then fractionated and collected. In biochemistry, ultracentrifugation is valuable for separating biomolecules and analyzing their physical properties.
Radioactive thorium was used in the 1950s and 60s to treat tuberculosis and other benign diseases (including children), with serious consequences (see Peteosthor). A stabilized suspension of colloidal thorium(IV) oxide, co-developed by António Egas Moniz (1874-1954), was used from 1929 under the trade name Thorotrast as an X-ray contrast agent for angiography in several million patients worldwide until it was banned in the mid-1950s. It accumulates in the reticulohistiocytic system and can lead to cancer due to locally increased radiation exposure. The same is true for cholangiocarcinoma and angiosarcoma of the liver, two rare liver cancers. Carcinomas of the paranasal sinuses have also been described following administration of Thorotrast. Typical onset of disease is 30–35 years after exposure. The biological half-life of Thorotrast is approximately 400 years. The largest study in this area was conducted in Germany in 2004 and showed a particularly high mortality rate among patients exposed in this way. The median life expectancy over a seventy-year observation period was 14 years shorter than in the comparison group.
Trisomy 21 Fetal trisomy of chromosome 21 is the cause of Down syndrome. This trisomy can be detected by analysis of cffDNA from maternal blood by massively parallel shotgun sequencing (MPSS). Another technique is digital analysis of selected regions (DANSR). Such tests show a sensitivity of about 99% and a specificity of more than 99.9%. Therefore, they cannot be regarded as diagnostic procedures but may be used to confirm a positive maternal screening test such as a first trimester screening or ultrasound markers of the condition.
== Medical uses == Metoprolol is used for a number of conditions, including angina, acute myocardial infarction, high blood pressure, supraventricular tachycardia, ventricular tachycardia, congestive heart failure, and prevention of migraine headaches. It is an adjunct in the treatment of hyperthyroidism. Both oral and intravenous forms of metoprolol are available for administration. The different salt versions of metoprolol – metoprolol tartrate (short acting) and metoprolol succinate (long acting) – are significantly different from one another and should not be substituted for one another except when used as directed by a medical professional. Off-label uses include supraventricular tachycardia and thyroid storm.
Sources: en.wikipedia.org
10 December – Foreign Secretary David Cameron threatens to withdraw co-operation with Scottish ministers following a meeting between Humza Yousaf, the First Minister of Scotland, and Turkish President Recep Tayyip Erdogan at the 2023 United Nations Climate Change Conference, which took place without the presence of a UK official and was consequently a breach of protocol. In response, Yousaf calls the threat "petty" and "misguided". 11 December – New modernised trains are introduced on the Glasgow Subway as part of a £288m upgrade of the city's underground rail system. The Foreign and Commonwealth Office is to move from its Abercrombie House offices in East Kilbride to an undisclosed location in Glasgow some time after 2025, it is announced, with His Majesty's Revenue and Customs moving from Queensway House to replace the FCO at Abercrombie House. 12 December – Five men are charged in connection with historic sexual abuse at Edinburgh Academy. Perth and Kinross Council provisionally approves a 100% increase in Council Tax on second homes. 13 December – Nuns Sister Sarah McDermott, 79, and Sister Eileen Igoe, 79, and carer Margaret Hughes, 76, are convicted of mistreating children at Smyllum Park, an orphanage in Lanark, from 1969 until its closure in 1981. 14 December – Robert O'Brien, aged 45, Andrew Kelly, 44, and Donna Marie Brand, also aged 44, are convicted of the 1996 murder of Caroline Glachan following a trial at the High Court in Glasgow. All three were teenagers at the time the crime was committed.
== Preparation == An aqueous solution of sodium silicate is acidified to produce a gelatinous precipitate that is washed, then dehydrated to produce colorless silica gel. When a visible indication of the moisture content of the silica gel is required, ammonium tetrachlorocobaltate(II) (NH4)2[CoCl4] or cobalt(II) chloride CoCl2 is added. This will cause the gel to be blue when dry and pink when hydrated. Due to a link between the cobalt chloride and cancer, it has been forbidden in Europe for use in silica gel. An alternative indicator is methyl violet, which is orange when dry and green when hydrated.
A radium industry developed, using radium in creams, beverages, chocolates, toothpastes, and soaps. It took a relatively long time for radium and its decay product radon to be recognized as the cause of the observed effects. Radithor, a radioactive agent consisting of triple-distilled water in which the radium isotopes 226Ra and 228Ra were dissolved so that it had an activity of at least one microcurie, was marketed in the United States. It was not until 1932, when the prominent American athlete Eben Byers, who by his own account had taken about 1,400 vials of Radithor as medicine on the recommendation of his physician, fell seriously ill with cancer, lost many of his teeth, and died shortly thereafter in great agony, that strong doubts were raised about the healing powers of Radithor and radium water.
== Advantages and disadvantages == Advantages include minimal overlap in metal signals meaning the instrument is theoretically capable of detecting 100 parameters per cell, entire cell signaling networks can be inferred organically without reliance on prior knowledge, and one well-constructed experiment produces large amounts of data. Disadvantages, in the case of CyTOF, include the practical flow rate is around 500 cells per second versus several thousand in flow cytometry and current reagents available limit cytometer use to around 50 parameters per cell. Additionally, mass cytometry is a destructive method and cells cannot be sorted for further analysis. In the case of IMC, the resolution of the data is relatively low (1μm2/pixel), the technique is as well destructive, acquiring of the data is also very slow, and it requires specialized expensive equipment and expertise.
== Pharmacology == Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria. In individuals with paroxysmal nocturnal hemoglobinuria, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular (within the liver or spleen) hemolysis. By binding to and inhibiting C3, pegcetacoplan helps regulate complement activation, thereby reducing red blood cell destruction, anemia, blood clot formation, and improving bone marrow function. This targeted mechanism of action makes pegcetacoplan the first-in-class medication for the treatment of paroxysmal nocturnal hemoglobinuria, offering a promising therapeutic approach to address the underlying complement dysregulation in this condition.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.